Search results for genzyme
Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced that they have entered a major strategic alliance in which Genzy
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corporation (NASDAQ: GENZ) today reported financial results for the full year and fourth quarter of 2007 and provided an outlook for continued strong growth in 2008 and beyond.
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corp. (Nasdaq: GENZ) announced the U.S. launch of the phosphate binder Renvela® (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to se
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corp. (Nasdaq: GENZ) announced the withdrawal of the European application to extend the Evoltra® (clofarabine) product label to include the treatment of elderly patients with acute myeloid le
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corp. (Nasdaq: GENZ) announced today that it will build a major new research and development center in Beijing. The initiative is an important element in Genzyme's ongoing global expansion a
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corporation (NASDAQ: GENZ) reported results for the first quarter of 2008, which featured excellent revenue growth, continued operating leverage, a significant increase in non-GAAP profit, an
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corp. (NASDAQ: GENZ) reported today that a preliminary analysis of data from an ongoing open-label Phase 2 clinical trial of its investigational oral therapy Genz-112638 showed that the compo
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corporation (Nasdaq: GENZ) announced that it has submitted marketing applications in both the United States and the European Union for Mozobil™ (plerixafor), a product candidate intended to e
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Genzyme Corp. (Nasdaq: GENZ), a global leader in biotechnology, and Medicines for Malaria Venture (MMV), a not-for-profit virtual research and development (R&D) organization dedicated to reducing the
read more »
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Posted by
worldpharmanews
539 days ago
(http://www.worldpharmanews.com)
Category: Research & Development |
Discuss Add this link to... Bury
